Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBITDA: 2009-2024

Historic EBITDA for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to $29.9 million.

  • Amicus Therapeutics' EBITDA rose 58.22% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 529.46%. This contributed to the annual value of $29.9 million for FY2024, which is 141.26% up from last year.
  • Per Amicus Therapeutics' latest filing, its EBITDA stood at $29.9 million for FY2024, which was up 141.26% from -$72.4 million recorded in FY2023.
  • Amicus Therapeutics' 5-year EBITDA high stood at $29.9 million for FY2024, and its period low was -$238.6 million during FY2020.
  • In the last 3 years, Amicus Therapeutics' EBITDA had a median value of -$72.4 million in 2023 and averaged -$83.3 million.
  • As far as peak fluctuations go, Amicus Therapeutics' EBITDA decreased by 3.28% in 2022, and later soared by 141.26% in 2024.
  • Over the past 5 years, Amicus Therapeutics' EBITDA (Yearly) stood at -$238.6 million in 2020, then rose by 15.87% to -$200.7 million in 2021, then dropped by 3.28% to -$207.3 million in 2022, then skyrocketed by 65.07% to -$72.4 million in 2023, then soared by 141.26% to $29.9 million in 2024.